Neostigmine
- Generic Name
- Neostigmine
- Brand Names
- Bloxiverz, Prevduo, Prostigmin
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N2O2
- CAS Number
- 59-99-4
- Unique Ingredient Identifier
- 3982TWQ96G
- Background
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
- Indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
- Associated Conditions
- Curarization therapy, Myasthenia Gravis, Neuromuscular Blockade, Postoperative Urinary Retention (POUR), Acute Colonic Pseudo-Obstruction, Post-operative intestinal atony
- Associated Therapies
- -
Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05993390
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 118
- Registration Number
- NCT05887375
- Locations
- 🇺🇸
University Hospital, Columbia, Missouri, United States
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 235
- Registration Number
- NCT05794503
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT05724550
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongrogu, Korea, Republic of
Perioperative Respiratory Adverse events_sugammadex
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT05354466
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 90
- Registration Number
- NCT05342818
- Locations
- 🇸🇦
Sharurah Armed Forces Hospital, Sharurah, Saudi Arabia
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT05116930
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
- Conditions
- Interventions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-10-04
- Target Recruit Count
- 113
- Registration Number
- NCT05066035
Neostigmine Route for Acute Colonic Pseudo Obstruction
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 90
- Registration Number
- NCT04951726
- Locations
- 🇺🇸
Los Angeles University of Southern California Medical Center, Los Angeles, California, United States
Comparison Of Different Doses Of Intrathecal Neostigmine In Prevention Of Post-Dural Puncture Headache
- Conditions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 274
- Registration Number
- NCT04905953
- Locations
- 🇪🇬
Faculty of Medicine- Cairo University, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.